# Rocksteady → Beebop: thrombocytopenia research report

**Request:** `BEEBOP_RESEARCH_REQUEST_2026-10-02.md` · **Branch:** `claude/oligo-challenge-data-4um5mi`
**Inventory commit:** `c530bb7` · **Scientist baseline:** v0.9 frozen + v0.10 Evidence Watch overlay
**Research window:** 2026-10-02 / 2026-10-03 UTC

**Round rules observed.** No validated dataset row, label, scientific adjudication or model was
changed by this research. SafeSense was not acquired or ingested. The final clinical sequence
classifier remains blocked and was not run. No purchase, subscription, credential or author/sponsor
contact occurred. Acquired material is in `curation/research_staging/`, which is not `data/`.

---

## 1. Proposal dispositions

| # | Proposal | Disposition |
|---|---|---|
| 1 | Prioritise condition-level numerical human platelet observations from Sewing 2017 S1 and primary Slingsby sources | **ACCEPT for Sewing — done. REJECT the Slingsby premise:** its raw data does not exist publicly |
| 2 | 2,347 cells are not 2,347 independent observations; six-of-six agreement is transcription evidence | **ACCEPT IN FULL — you are right; corrected in the narrative and quantified** |
| 3 | Keep SafeSense quarantined; request precisely `mmc4.csv` if inaccessible | **ACCEPT — and no request is needed: the route is open.** Quarantine held |
| 4 | Reconcile the 24 pooled units and 21 nested trials before any total; audit the 22 | **ACCEPT — done. The 22 audits down to 19** |
| 5 | Investigate primary sequence/chemistry for the 9 missing sequences and 16 missing maps | **ACCEPT — PARTIALLY DONE, and the undone half is the sweep's largest gap** |
| 6 | Keep platelet counts, interaction/activation, bleeding, coagulation and intended pharmacology separate; no new modelling | **ALREADY COMPLETE — no modelling performed** |

### 1 — Sewing staged; the Slingsby premise is wrong

Sewing 2017 S1 is staged at condition level: **2,347 numeric cells**, each carrying endpoint block,
row label, column header, **exact cell locus**, control class and resolved construct, with the
unchanged workbook and its checksum beside it. A side-by-side block layout initially dropped
`(AC)9 + LNA` — one of the three scientist matched contrasts the file exists to support — so the
parser now climbs the column band for the governing header. All four matched contrasts resolve,
including the ODN 2395 PS/PO pair.

**Slingsby publishes no raw data, and this closes a request rather than opening one.** Slingsby 2022
*is* `10.3324/haematol.2020.260059` (PMC8804562) — the 157-row block and the largest human in-vitro
source in the dataset. Its supplementary archive was retrieved in full (**1,848,710 bytes**,
`sha256 b43b75e4bdd630e0c2d8f89e287fb0ef0c20acc7186b6195588724666c944406`) and contains only
figure/table images and a methods appendix. The article carries **no data-availability statement and
no deposit**; its Table 1 sequences are published as an image; the full text contains **zero**
16–24mer ACGT strings. Per-donor Slingsby values are therefore unobtainable by any route short of
author contact, which this round does not authorise. Do not spend further effort on it.

**Figure 6 coordination:** Sewing Figure 6 is whole-blood cytokine data (MCP-1, with R848 / CpG /
poly-dC controls) — immunostimulation, not platelet readouts. It is staged with the rest for
completeness but it is the complement/immunotoxicity session's material, not thrombocytopenia
evidence, and I am not claiming it as such.

### 2 — The overclaim, withdrawn and quantified

You are right and I accept it without reservation. The precise position:

- **Six-of-six contrast agreement is transcription and consistency evidence, not biological
  validation.** The scientist's adjudicated 0–3 score and this dataset's grade derive from the *same
  publications*. Their agreement shows two independent curation efforts read the same sources the
  same way. Nothing in it replicates an experiment. An earlier draft of mine called them "two
  independently built datasets" agreeing — true of the curation, false of the evidence.
- **A numeric cell is not an observation.** Of 2,347 staged cells, **163 resolve to a named
  construct** across 12 constructs and **190 are controls**; the remainder are concentration axes,
  heparin comparators, and published means and standard deviations recomputable from the replicates
  beside them. Several staged cells are therefore derived values, not independent measurements.
- **What is genuinely new versus reconstructed:** *nothing acquired in this round is new evidence.*
  Everything recovered reconstructs an existing publication's own reported measurements at finer
  grain. The gain is grain and auditability, not new biology.

Both corrections are now in the narrative PDF, carried visibly as a correction rather than quietly
restated, and on the face of the staging manifest.

### 3 — SafeSense: quarantine held, and no request is needed

I did not acquire, open or ingest it. I established the access route only, which is what the
proposal asks for before requesting a file:

| | |
|---|---|
| DOI | `10.1016/j.omtn.2026.103035` |
| Resolved | PMID **42633286**, PMCID **PMC13499347** |
| Open access | **Yes** — Europe PMC `isOpenAccess=Y` |
| Licence | **CC BY-NC-ND** |
| Supplementary archive | `…/PMC13499347/supplementaryFiles` → **HTTP 200, application/zip** |

**So `mmc4.csv` is openly available and there is no access barrier to report and no file to request
from Oscar.** Acquisition ownership stays where German's own action queue puts it (ACT-010-04,
German + Oscar); I am not taking it.

**One flag worth more than the access answer: the licence is CC BY-NC-**ND**.** NoDerivatives is a
materially harder constraint than NonCommercial for a dataset that would restructure SafeSense
records into a schema — that is precisely a derivative. Extracting *facts* is a different act from
redistributing a modified work, but the distinction needs a deliberate decision rather than an
assumption. This belongs with the rights question in §7, not with acquisition.

I have not substituted the atlas headline population for anything, and no deduplicated trial count
in this dataset draws on it.

### 4 — Pooled reconciliation and the audit of the 22

Reconciliation was already in place at `b5abc7b`: **23 nesting edges covering 21 trials** in
`data/study_nesting_ledger.csv`, each established by **arithmetic agreement on arm sizes** against
the pooling source's own table rather than by name similarity. No participant total is published;
`study_counts.csv` records participants as **not summable** with the reason.

The audit you asked for is new. The **22** was a curator classification, so
`scripts/audit_toxicity_denominator.py` applies four tests per unit — monitoring actually *quoted*
rather than absence merely reported; dose *and* duration stated; a platelet-specific at-risk
denominator present; a retrievable locus cited:

| Test | Pass |
|---|---|
| T1 monitoring quoted, not absence language | 22/22 |
| T2 exposure (dose and duration) stated | 22/22 |
| T3 platelet-specific at-risk denominator | 20/22 |
| T4 retrievable locus cited | 21/22 |
| **Survives all four** | **19/22** |

**19 is the figure to quote.** No unit rests on absence language alone — the eight evaluability
downgrades made at `b5abc7b` had already removed those. QC now prints the audited figure and
instructs the reader to use it.

**Clean sequence-linked comparators: found, and they are controls, not negatives.**
`data/controls_inventory.csv` enumerates **31 control records over 26 compounds** — 4 isosequential
backbone pairs, 4 chemistry-variant comparators, 15 vehicle/concurrent-control arms, 4
intended-pharmacology comparators — each with its permitted *and prohibited* use. The strongest is
`ODN2395_Thio` (PS 21, 113 rows) against `ODN2395` (PS 0, 24 rows): same 22-mer, backbone the only
variable. **Qualified clinical negatives remain 0** and nothing here changes that; the controlling
limitation stands.

**An omission of my own that this proposal exposed.** Phase 2 requires the narrative to open with
"an executive summary of the dataset(s) generated, **and positive/negative controls included**". I
had been leading with "zero qualified clinical negatives", which is accurate about a clinical label
and reads as though the dataset had no controls. It has several and they are among its strongest
content. Corrected.

### 5 — Characterisation: accepted, half-done, and the undone half is named

**Done.** Composed versus source-verbatim is now explicit per row
(`modification_map_notation`), and the result is uncomfortable and worth stating plainly: on the 34
human-clinical compounds, **0 of 34 position-chemistry maps are source-verbatim** — all 18 that
exist are composed. On the 48 human-laboratory compounds, 2 of 48 are verbatim. A populated map is
not a verified one, exactly as you said.

**The exception table you asked for exists**: `curation/scientist_v09/conflicts.csv`, 21 entries,
nothing silently corrected. Four carry atom-count proofs — tofersen is 15 PS + 4 PO, not `full_PS`
(its formula contains S15, not S19); patisiran contains **no fluorine** though its row claims 2′-F;
aprinocarsen is a first-generation uniform PS oligodeoxynucleotide, not a gapmer; `TOLG072` and
`TOLG073` are one molecule under two ids. All four are label changes and all four are held.

**Not done, and this is the sweep's largest internal gap.** An adversarial audit of the coverage log
found **zero queries** across all nine families for `purity`, `patent`, `stereochem`, `FDA` or
`data availability` — the exact routes your proposal names ("regulatory assessments … patent
sequence/construct sources and article data-availability links"). The sweep was literature- and
archive-shaped and never turned toward chemistry. **`purity_pct` therefore remains 0/259 and this
round did not move it.** I am reporting that as an uncovered half rather than implying coverage; it
is the first item of the proposed next package in §3.

### 6 — Outcome separation: already complete

`readout_category` already separates platelet count, platelet activation, platelet binding/
aggregation, immunogenicity, megakaryocyte, histopathology, viability and coagulation.
Intended pharmacology is carried as a distinct flag on the study registry with a per-unit reason,
and the three units it excludes are named. **No model was trained, no model eligibility changed, and
the sequence-only clinical classifier remains BLOCKED and retracted.**

---

## 2. Current inventory at commit `c530bb7`

| | |
|---|---:|
| Measured constructs (≥1 row) | **229** |
| Catalog entries | 259 |
| Primary source documents | **70** |
| Measurement rows | 1,959 |
| — human clinical | 1,002 |
| — human laboratory (in vitro 426 + ex vivo 25) | **451** |
| — animal support (appendix) | 497 |
| — unresolved (multi-species 4 + unspecified 5) | 9 |

**The 30-record gap between 229 measured and 259 catalogued is the Crooke pooled panel**, whose rows
cannot be attributed per sequence; they correctly carry no measurements.

### Human study grain

| | |
|---|---:|
| Evidence units resolved | 85 |
| Typed as a trial | 56 |
| Carrying ≥1 measurement row | 39 |
| **Surviving the four-test audit** | **19** |
| Pooled analyses (not trials) | 24 |
| Declared pool↔trial overlaps | 23 edges / 21 trials |
| Independent cohorts | **not established** — cohort-level identity was not resolved this round |
| Participants | **not summable**; denominators overlap across nested strata |

### Source-verified characterisation coverage, with denominators

**Dataset-wide first, subsets beside it.** Crank's delegation directs this endpoint to report
modification-map coverage at the dataset-wide denominator rather than the clinical subset alone;
both are given here, each with its denominator stated, because the subsets are what the human-first
reading needs and the dataset-wide figure is what a reviewer will quote.

| | **dataset-wide (259 cpds)** | human clinical (34 cpds) | human laboratory (48 cpds) |
|---|---:|---:|---:|
| sequence text | **200/259** | 25/34 | 25/48 |
| position-chemistry map | **44/259 (16%)** | 18/34 | 20/48 |
| — of which **source-verbatim** | **2/259** | **0/34** | **2/48** |
| ps_count | — | 26/34 | 27/48 |
| purity **method** | 11/259 | 11/34 | 2/48 |
| purity **value** | **0/259** | **0/34** | **0/48** |

Provenance tag for the above: **measured-by-me** at commit `989a581`, computed directly from
`data/oligos.csv` and `data/measurements.csv`, not read from a generated artifact or from prose.

Row-level: **628 of 1,959 (32%)** carry `verified_against_source`; human clinical 382/1,002 (38%),
human laboratory 240/451 (53%). 48 rows cite an abstract rather than a numbered locus.

### Remaining qualification blockers

1. **`purity_pct` 0/259.** Numeric acceptance criteria are withheld as Confidential Commercial
   Information (FDA FOIA Exemption 4, with page-count stamps: nusinersen NDA 209531 "136 Page(s)
   has been Withheld in Full as b4"; imetelstat NDA 217779 releases 24 of 156 and the withheld
   section is "Characterization of Drug Substance and Impurities"). Method recovered for 11.
2. **No source-verbatim position chemistry on the clinical subset** (0/34).
3. **Zero qualified clinical negatives** — scientist-controlled, unchanged.
4. **Independent cohort identity unresolved.**
5. **224 rows of closed-access rights** awaiting a decision (§7).
6. **Scientist approval outstanding**; gate SRQ-TMB-012 not cleared. Not release-eligible.

---

## 3. Acquisition plan, and work performed versus proposed

**Performed.** Sewing 2017 S1 retrieved, verified and staged at condition level. Slingsby 2022
supplementary archive retrieved in full and established as containing no raw data. SafeSense access
route established without acquisition. Control-ASO sequences recovered (below). Rights resolved for
all 70 sources. 15 of 20 resources searched.

**Proposed, not performed** — in priority order:

| # | Work | Expected qualified yield | Dependency |
|---|---|---|---|
| 1 | **The chemistry half of proposal 5**: regulatory assessments, patent sequence listings, WHO INN documents and data-availability statements for the 9 clinical compounds lacking sequence and the 16 lacking maps | **unknown** — not established; the sweep never queried these routes | none |
| 2 | Promote staged Sewing values to replicate-level evidence for the mechanistic lane | 163 construct-resolved values over 12 constructs, 4 matched contrasts | German (SRQ-TMB-006) + Oscar |
| 3 | Resolve independent cohort identity across the 23 nesting edges | unknown | none |
| 4 | ClinicalTrials.gov posted-results extraction for the verified NCTs with `hasResults=true` | unknown; public domain, so rights-free | none |
| 5 | Source-verbatim verification of the 18 composed clinical maps | 18 maps re-grounded or contradicted | German on contradictions |

**Shared-source ownership.** SafeSense `mmc4.csv` — German + Oscar (ACT-010-04); route established,
not taken. Control-ASO supplement — German + Oscar (ACT-010-05); **already retrieved by the sweep**,
so that action is closed on access and open only on adjudication. Sewing Figure 6 cytokine data —
complement/immunotoxicity session, flagged not claimed.

### Staged file provenance

| File | Bytes | sha256 | Committed |
|---|---:|---|---|
| `sewing2017_pone.0187574_S1.xlsx` | 54,955 | `cd4d4b09…a3fc` | yes |
| `sewing2017_condition_level.csv` | 563,211 | — (derived) | yes |
| Slingsby supplementary archive | 1,848,710 | `b43b75e4…4406` | no (inventoried) |
| omtn cASO supplementary archive | 22,626,304 | see inventory | no (inventoried) |
| 10 further full texts / archives | — | see inventory | no (inventoried) |

Bulk third-party content is **not** committed; `curation/research_staging/staged_inventory.csv`
records every retrieved file with byte count, sha256, original filename, retrieval URL and inner
file/sheet inventory, so any of it is re-fetchable and verifiable. The `.gitignore` in that folder
states the rule and its one exception.

---

## 4. The twenty-source coverage log

`curation/research_staging/search_coverage_log.csv` — one row per named resource, with exact
queries, the search window, result identifiers, outcome, barrier class and verbatim barrier detail.
`sweep_all_resource_rows.csv` holds all 31 rows the sweep reported, including sub-endpoints.

**15 of 20 searched. 5 were not, and are recorded as not searched rather than as null results:**

| Resource | Barrier class | Observed |
|---|---|---|
| ResearchRabbit | service_login | no query ever executed; marketing site, app behind login |
| Undermind | service_login | no query ever executed |
| Elicit | technical_block | every search request blocked |
| Consensus | service_login | Cloudflare-challenged; no query executed |
| Comparative Toxicogenomics Database | technical_block | every path tested, including the documented `batchQuery.go` endpoint |

### Corrections applied to the sweep's own log

An adversarial audit of the log found real defects. **27 corrections** are recorded in
`sweep_corrections.csv` with the original claim preserved beside each:

- **3 rows claimed `searched: true` having retrieved nothing** — the exact thing your brief
  forbids, and in each case the row's own notes asserted the correct standard. Forced to `false`.
- **1 fabricated title removed.** A candidate logged as an oligonucleotide platelet study
  (`10.1158/1538-7445.am2025-6835`) had "(oligonucleotide)" inserted into its title; the real
  study's compound is **dasatinib**, a tyrosine kinase inhibitor. Deleted, not re-ranked.
- **2 disproven yields corrected.** The Slingsby supplement was logged as carrying "~60–200
  per-donor observations", inferred from counting the word "donor" in body text; opening the archive
  disproved it. Downgraded to 0.
- **1 conflated identifier flagged unusable** — one PMO candidate merges three distinct documents
  under a single title/identifier pair.
- **20 cross-family duplicates merged.** Each family's candidate list was standalone; 119 raw
  candidates deduplicate to **78** on any shared identifier.
- **Search date corrected** from a uniform back-dated `2026-10-02` to the true
  `2026-10-02/2026-10-03` window. The rollover is material: it is what unblocked one resource.

### Gaps in the sweep, stated rather than papered over

- **SafeSense was never searched by any family** — zero hits for `safesense`, `103035` or `mmc4`
  across all nine files, although the brief named both the DOI and the file. I closed it manually
  (§1.3); it should not have needed closing.
- **The chemistry half was never searched** (§1.5): zero queries for purity, patents,
  stereochemistry, FDA assessments or data-availability statements.
- **The named matched contrasts were not carried into the archives.** `AC-series` appears in zero
  files; `ODN2395` in only two. The six archives most likely to hold a matching deposit were never
  queried for them.
- **Mechanism terms never queried**: `TLR7`, `thrombopoietin`/`c-Mpl`, `C3d`, `PS-ASO` — all zero,
  despite priority-1 candidates whose stated value depends on them.
- **PubMed's relevance count is unauditable against its own stated criterion.** The log says
  filtering required a platelet term *in the title*; 62 of the 93 retained titles contain none.
  Most are genuinely relevant trials, so the number is plausible and the *rule* is wrong — treat 93
  as unfiltered.

### One substantive recovery

**The cASO control sequences are recovered in full**, closing the open item in German's
`Control_ASO_Review_v0.10` where they read `PENDING TABLE S2`. From Table S2 of
`10.1016/j.omtn.2026.103051` (PMID 42733805, PMC13571576), page 20 of `mmc1.pdf`, all 20-nt uniform
2′-MOE/PS with per-linkage notation, GC%, Tm and ΔG:

```
cASO7   U*A*G*C*G*C*C*A*G*U*U*C*G*U*A*U*A*U*C*G
cASO9   U*A*G*U*U*G*A*C*G*G*A*U*C*G*U*A*C*U*C*G
cASO11  C*G*C*C*G*U*A*U*U*G*U*G*C*U*C*U*A*U*C*G
```

**This closes a chemistry gap, not an endpoint gap.** That paper contains zero occurrences of
"platelet", "GPVI" or "thrombocyt". It does not make these compounds controls for *this* endpoint —
German's rule CTRL-R01 (a low-response control is valid only for the tested endpoint and model) and
CTRL-R03 (no in-vitro control may be labelled a clinical negative) both still apply, and the
sequences are reported for adjudication, not adopted.

---

## 5. Paper / supplement / data-access table

`curation/research_staging/acquisition_candidates.csv` carries all 78 deduplicated candidates with
full title, authors/year, identifier, link, where discovered, publisher/repository, required file,
endpoint gap, expected usable observations, access attempts, outcome and priority. 28 are priority 1
and 35 are human in vitro. The highest-value rows:

| Title | Identifier | Required file | Gap | Access outcome | Pri |
|---|---|---|---|---|---|
| Sewing 2017, in-vitro risk factors for thrombocytopenia | `10.1371/journal.pone.0187574` | S1 raw workbook | replicate-level data for the mechanistic lane | **retrieved, CC BY** | 1 |
| Lundberg-Slingsby 2022, 2′MOE ASOs activate platelets via GPVI | `10.3324/haematol.2020.260059` | per-donor panels | — | **retrieved; contains no raw data** | — |
| "To scramble or not", control ASOs | `10.1016/j.omtn.2026.103051` | Table S2 in `mmc1.pdf` | cASO7/9/11 exact sequences | **retrieved; sequences recovered** | 1 |
| SafeSense ASO adverse-event atlas | `10.1016/j.omtn.2026.103035` | `mmc4.csv` | treatment-level records | **route open, not taken (owner: German+Oscar)** | 1 |
| Zaslavsky 2021, Thrombosis Research | `10.1016/j.thromres.2021.01.006` | full text | 56 dataset rows, closed-access | **NIHMS author manuscript retrieved free** | 2 |

---

## 6. Inaccessible material, classified

| Class | Items | Evidence |
|---|---|---|
| **Confirmed publisher paywall** | pelacarsen platelet-reactivity, `10.1007/s11239-023-02818-6` | Springer landing page states "Buy article", **USD 39** — price *verified as displayed on 2026-10-03*, not inferred. Europe PMC `isOpenAccess=N`, no PMCID; no free route exists |
| **Confirmed publisher paywall, free route found** | Thrombosis Research, `10.1016/j.thromres.2021.01.006` | Elsevier interstitial carries `meta name="tdm-reservation" content="1"`; **NIHMS author manuscript in PMC used instead** |
| **Confirmed paywall, no free route** | J Thromb Haemost CpG ODN CLEC-2/P2Y12 paper and its comment/reply (PMIDs 28296036, 29052937, 29052966) | `isOpenAccess=N`, no PMCID, so no free endpoint exists to attempt |
| **Service login / subscription** | ResearchRabbit, Undermind, Consensus | app behind login; no query executed |
| **Technical block** | Elicit; CTD; Europe PMC `FULL_TEXT:` field index (hitCount 0 on valid phrases, worked around unfielded); Dryad file downloads (HTTP 401/403) | verbatim statuses in the log |
| **Broken link** | NCBI PMC OA Web Service `oa.fcgi` — HTTP 404 on three ids including one demonstrably in the OA subset; endpoint retired, articles not missing. ClinicalTrials.gov legacy v1 API — retired, HTTP 404 | |
| **Missing supplement** | Europe PMC `supplementaryFiles` for PMC8264460 returned HTTP 200 with a 296-byte empty archive | recovered via eutils `efetch` |
| **Unresolved citation** | `10.1182/blood-2025-204` — real (Crossref resolves it: anti-PF4 antibodies as a mediator of ASO-induced thrombocytopenia) but an unindexed conference abstract with no PMID/PMCID | labelled as such, not left beside peer-reviewed sources |

**No subscription, entitlement or price is asserted beyond the one verified above.** Free and legal
routes were taken first in every case where one existed.

**Request to Oscar: none.** Every file this round needed is either retrieved, openly reachable, or
established as not existing. The two shared-ownership files (`mmc4.csv`, the cASO supplement) are
reachable without a request, and acquisition stays with German and Oscar by their own action queue.

---

## 7. What needs whose approval

**Oscar — implementation and scope**
1. **The 224-row rights decision.** Resolving all 70 sources against publisher-declared licences
   moves openly releasable rows from an assumed ~49% to **1,735/1,959 (88%)**: 748 public domain +
   987 CC-licensed. Only **224 rows across 17 closed-access sources** need a call, and the top five
   are 181 of those 224. My earlier "half the dataset" figure was wrong and is withdrawn.
2. **The non-commercial question.** **758 rows** carry an NC clause (607 BY-NC, 140 BY-NC-SA, 11
   BY-NC-ND). Phase 2 asks for terms allowing open public access "such as through a creative commons
   license", which NC formally satisfies — but it restricts commercial reuse, and that should be a
   decision rather than a default.
3. **SafeSense is CC BY-NC-**ND**.** NoDerivatives bites harder than NonCommercial for a
   restructured dataset. Worth settling before staging begins, not after.
4. **Whether to run the chemistry half** of proposal 5 (§1.5) as the next package.
5. **Whether the three implemented commits from the superseded September 30 wording stand** — raised
   in the previous review reply and still open.

**German — scientific adjudication**
6. **The 21-entry exception table** (`conflicts.csv`), including the four atom-count-proofed
   corrections, all unapplied.
7. **v0.9 `Position_Chemistry` records eplontersen as 19 PS**, propagated from inotersen; the
   compound is mixed-backbone. Needs correcting at source; my composed map is reverted, not patched.
8. **The recovered cASO7/9/11 sequences** — adopt into the control library or not, under CTRL-R01
   and CTRL-R03. They close a chemistry gap and carry no platelet evidence.
9. **Promotion of staged Sewing values**, gated on SRQ-TMB-006.
10. **That 0 of 34 clinical position-chemistry maps are source-verbatim** — whether composed maps are
    acceptable for the submission, or must be re-grounded.
11. **Five absolute-grade disagreements** on MCON-TMB-002 to 006; direction agrees 6/6, magnitude
    does not.

**Neither** — the sequence-only clinical classifier stays blocked, qualified clinical negatives stay
at 0, and nothing in this round unlocks either.

---

**RESEARCH COMPLETE — AWAITING OSCAR'S IMPLEMENTATION AUTHORIZATION AND GERMAN'S SCIENTIFIC ADJUDICATION**
